| Citation: |
MA Jianming, REN Tingting. Clinical Diagnosis and Treatment of Lacrimal Gland Adenoid Cystic Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1153-1159. DOI: 10.3971/j.issn.1000-8578.2023.23.0627
|
Lacrimal gland adenoid cystic carcinoma (LGACC) is the most common primary malignant epithelial tumor of the lacrimal gland and has the characteristics of high recurrence rate, neurotropic growth, and risk of distant metastasis. The clinical manifestation is mainly a mass in the lacrimal gland area with a poor specificity. The combination of MRI and CT is important in the diagnosis of LGACC, and PET/CT is of great value in determining the nature and metastasis of LGACC. Histopathological examination is the gold standard for diagnosis, and the type of histopathology is significant for predicting the prognosis of patients. At present, the most commonly used treatment for LGACC is surgical resection combined with postoperative local radiotherapy. However, the overall prognosis is poor after active treatment because the pathogenesis of LGACC remains unclear. This article will combine relevant literature and the author's clinical experience to review the epidemiology, clinical manifestations, imaging examination, histopathological changes, treatment, and prognosis of LGACC. Results will contribute to improve the quality of diagnosis and treatment and the prognosis of patients.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Emerick C, Mariano FV, Vargas PA, et al. Adenoid Cystic Carcinoma from the salivary and lacrimal glands and the breast: Different clinical outcomes to the same tumor[J]. Crit Rev Oncol Hematol, 2022, 179: 103792. doi: 10.1016/j.critrevonc.2022.103792
|
| [2] |
Benali K, Benmessaoud H, Aarab J, et al. Lacrimal gland adenoid cystic carcinoma: report of an unusual case with literature review[J]. Radiat Oncol J, 2021, 39(2): 152-158. doi: 10.3857/roj.2021.00122
|
| [3] |
Cantù G. Adenoid cystic carcinoma. An indolent but aggressive tumour. Part A: from aetiopathogenesis to diagnosis[J]. Acta Otorhinolaryngol Ital, 2021, 41(3): 206-214. doi: 10.14639/0392-100X-N1379
|
| [4] |
Anjum S, Sen S, Pushker N, et al. Prognostic impact of Notch1 receptor and clinicopathological High-Risk Predictors in lacrimal gland adenoid cystic carcinoma[J]. Acta Ophthalmol, 2021, 99(8): e1467-e1473.
|
| [5] |
Ashok Kumar P, Wang D, Huang D, et al. Current Trends in the Management of Epithelial Lacrimal Gland Tumors: A Retrospective National Cancer Database Analysis[J]. Cureus, 2022, 14(7): e27109.
|
| [6] |
Yang J, Zhou C, Wang Y, et al. Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma[J]. BMC Ophthalmol, 2019, 19(1): 125. doi: 10.1186/s12886-019-1110-5
|
| [7] |
Gunduz AK, Yesiltas YS, Shields CL. Overview of benign and malignant lacrimal gland tumors[J]. Curr Opin Ophthalmol, 2018, 29(5): 458-468. doi: 10.1097/ICU.0000000000000515
|
| [8] |
von Holstein SL, Coupland SE, Briscoe D, et al. Epithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological survey[J]. Acta Ophthalmologica, 2013, 91(3): 195-206. doi: 10.1111/j.1755-3768.2012.02402.x
|
| [9] |
Jaso J, Malhotra R. Adenoid cystic carcinoma[J]. Arch Pathol Lab Med, 2011, 135(4): 511-515. doi: 10.5858/2009-0527-RS.1
|
| [10] |
Liu R, Li J, Zhang X, et al. Differences in clinical features and prognosis between orbit adenoid cystic carcinoma and adenocarcinoma: a study from the SEER 18 database[J]. Tumori, 2023, 109(1): 61-70. doi: 10.1177/03008916211070328
|
| [11] |
Liu R, Shi JT, Ge X, et al. Similar therapeutic effects of (125)I seed radiotherapy and gamma-ray radiotherapy on lacrimal gland adenoid cystic carcinoma[J]. Int J Ophthalmol, 2021, 14(4): 547-553. doi: 10.18240/ijo.2021.04.11
|
| [12] |
侯萍, 张虹. 泪腺腺样囊性癌93例临床分析[J]. 天津医科大学学报, 2016, 22(6): 528-530. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYK201606020.htm
Hou P, Zhang H. Clinical analysis of 93 cases of lacrimal adenoid cystic carcinoma[J]. Tianjin Yi Ke Da Xue Xue Bao, 2016, 22(6): 528-530. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYK201606020.htm
|
| [13] |
Bernardini FP, Devoto MH, Croxatto JO. Epithelial tumors of the lacrimal gland: an update[J]. Curr Opin Ophthalmol, 2008, 19(5): 409-413. doi: 10.1097/ICU.0b013e32830b13e1
|
| [14] |
杨本涛, 王振常, 宋照亮, 等. 泪腺腺样囊性癌的CT和MRI诊断[J]. 临床放射学杂志, 2007, 26(3): 240-243. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFS200703010.htm
Yang BT, Wang ZC, Song ZL, et al. CT and MRI Diagnosis of Adenoid Cystic Carcinoma in the Lacrimal Gland[J]. Lin Chuang Fang She Xue Za Zhi, 2007, 26(3): 240-243. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFS200703010.htm
|
| [15] |
包兵, 沙炎. 泪腺腺样囊性癌的CT诊断[J]. 放射学实践, 2010, 25(6): 616-619. https://www.cnki.com.cn/Article/CJFDTOTAL-FSXS201006010.htm
Bao B, Sha Y. CT diagnosis of adenoid cystic carcinoma of the lacrimal gland[J]. Fang She Xue Shi Jian, 2010, 25(6): 616-619. https://www.cnki.com.cn/Article/CJFDTOTAL-FSXS201006010.htm
|
| [16] |
张淑慧, 王振常, 鲜军舫, 等. 泪腺腺样囊性癌的CT和MRI诊断[J]. 中国医学影像技术, 2007, 23(4): 507-509. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX200704008.htm
Zhang SH, Wang ZC, Xian JF, et al. CT and MRI diagnosis of adenocystic carcinoma of the lacrimal gland[J]. Zhongguo Yi Xue Ying Xiang Ji Shu, 2007, 23(4): 507-509. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX200704008.htm
|
| [17] |
Ceylanoglu KS, Konuk O. Clinical and radiologic outcomes of pleomorphic adenoma and adenoid cystic carcinoma of the lacrimal gland[J]. Arq Bras Oftalmol, 2022.
|
| [18] |
Qin W, Chong R, Huang X, et al. Adenoid cystic carcinoma of the lacrimal gland: CT and MRI findings[J]. Eur J Ophthalmol, 2012, 22(3): 316-319. doi: 10.5301/ejo.5000015
|
| [19] |
张红, 马建民, 张勇, 等. 泪腺腺样囊性癌高级别转化的临床病理学研究[J]. 中华眼科医学杂志(电子版), 2020, 10(5): 288-293. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYB202005007.htm
Zhang H, Ma JM, Zhang Y, et al. High-grade transformation in lacrimal adenoid cystic carcinoma: a clinico-pathological study[J]. Zhonghua Yan Ke Yi Xue Za Zhi(Dian Zi Ban), 2020, 10(5): 288-293. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYB202005007.htm
|
| [20] |
Szanto PA, Luna MA, Tortoledo ME, et al. Histologic grading of adenoid cystic carcinoma of the salivary glands[J]. Cancer, 1984, 54(6): 1062-1069. doi: 10.1002/1097-0142(19840915)54:6<1062::AID-CNCR2820540622>3.0.CO;2-E
|
| [21] |
柳睿, 张璇, 李静, 等. 泪腺腺样囊性癌不同病理组织学分型和分级间骨质破坏、神经侵犯和预后的差异[J]. 眼科学报, 2021, 36(8): 600-606. https://www.cnki.com.cn/Article/CJFDTOTAL-YKXB202108009.htm
Liu R, Zhang X, Li J, et al. Association of bone destruction, nerve invasion and prognosis of lacrimal gland adenoid cystic carcinoma with different histological types and grades[J]. Yan Ke Xue Bao, 2021, 36(8): 600-606. https://www.cnki.com.cn/Article/CJFDTOTAL-YKXB202108009.htm
|
| [22] |
Argyris PP, Pambuccian SE, Cayci Z, et al. Lacrimal gland adenoid cystic carcinoma with high-grade transformation to myoepithelial carcinoma: report of a case and review of literature[J]. Head Neck Pathol, 2013, 7(1): 85-92. doi: 10.1007/s12105-012-0383-2
|
| [23] |
Miyazaki M, Aoki M, Koga K, et al. Adenoid cystic carcinoma with high-grade transformation forming spindle cell component of the submandibular gland[J]. Auris Nasus Larynx, 2019, 46(6): 934-939. doi: 10.1016/j.anl.2019.01.014
|
| [24] |
Shah SA, Parikh L, Solanki R, et al. Lacrimal Gland Adenoid Cystic Carcinoma with High Grade Transformation: A Case Report and Current Concepts in Multi Modality Management[J]. Indian J Otolaryngol Head Neck Surg, 2022, 74(Suppl 2): 2599-2606.
|
| [25] |
Seethala RR, Hunt JL, Baloch ZW, et al. Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature[J]. Am J Surg Pathol, 2007, 31(11): 1683-1694. doi: 10.1097/PAS.0b013e3180dc928c
|
| [26] |
Chen Z, Jiang J, Fan Y, et al. Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review[J]. Diagn Pathol, 2023, 18(1): 65. doi: 10.1186/s13000-023-01354-4
|
| [27] |
Wan D, Zhou H, Zhang Y. Adenoid Cystic Carcinoma of the Breast in a Male Patient: A Case Report and Literature Review[J]. Front Oncol, 2022, 12: 905997. doi: 10.3389/fonc.2022.905997
|
| [28] |
Taghavi N, Yazdani F, Baghban AA, et al. Comparative Analysis of P63, Maspin and Matrix Metalloproteinase 2 Expression in Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of Salivary Glands[J]. J Dent Shiraz Univ Med Sci, 2020, 21(2): 95-101.
|
| [29] |
Yang C, Zhang L, Sanati S. SOX10 Is a Sensitive Marker for Breast and Salivary Gland Adenoid Cystic Carcinoma: Immunohistochemical Characterization of Adenoid Cystic Carcinomas[J]. Breast Cancer (Auckl), 2019, 13: 1178223419842185.
|
| [30] |
Xuan L, Yuan J, Zhang H, et al. Dominant cell type analysis predicts head and neck adenoid cystic carcinoma outcomes[J]. Ann Diagn Pathol, 2022, 56: 151867. doi: 10.1016/j.anndiagpath.2021.151867
|
| [31] |
Li QL, Huang P, Zheng CM, et al. Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis[J]. Oncotarget, 2017, 8(17): 29458-29473. doi: 10.18632/oncotarget.15297
|
| [32] |
Lee SJ, Chung KY, Kwon JE, et al. Expression of EpCAM in adenoid cystic carcinoma[J]. Pathology, 2018, 50(7): 737-741. doi: 10.1016/j.pathol.2018.08.013
|
| [33] |
Klein Nulent TJW, Valstar MH, Smit LA, et al. Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck[J]. BMC Cancer, 2020, 20(1): 519. doi: 10.1186/s12885-020-06847-9
|
| [34] |
Liu L, Zhao L, Zhang J, et al. Aberrantly expressed GFRalpha-1/RET in patients with lacrimal adenoid cystic carcinoma is associated with high recurrence risk: a retrospective study of 51 LACC cases[J]. Cancer Biol Med, 2021, 18(1): 199-205. doi: 10.20892/j.issn.2095-3941.2020.0271
|
| [35] |
Rui X, Huang Z, Chen R, et al. RPS3 Promotes the Metastasis and Cisplatin Resistance of Adenoid Cystic Carcinoma[J]. Front Oncol, 2022, 12: 804439. doi: 10.3389/fonc.2022.804439
|
| [36] |
Soares CD, de Caceres C, Rodrigues-Fernandes CI, et al. Prognostic importance of RUNX1 expression for head and neck adenoid cystic carcinoma[J]. Oral Dis, 2021, 27(2): 266-276. doi: 10.1111/odi.13522
|
| [37] |
Wu CC, Li H, Xiao Y, et al. Expression levels of SIX1, ME2, and AP2M1 in adenoid cystic carcinoma and mucoepidermoid carcinoma[J]. Oral Dis, 2020, 26(8): 1687-1695. doi: 10.1111/odi.13506
|
| [38] |
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin, 2017, 67(2): 93-99. doi: 10.3322/caac.21388
|
| [39] |
Rose GE, Gore SK, Plowman NP. Cranio-orbital Resection Does Not Appear to Improve Survival of Patients With Lacrimal Gland Carcinoma[J]. Ophthalmic Plast Reconstr Surg, 2019, 35(1): 77-84. doi: 10.1097/IOP.0000000000001177
|
| [40] |
Esmaeli B, Yin VT, Hanna EY, et al. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma[J]. Head Neck, 2016, 38(8): 1258-1262. doi: 10.1002/hed.24433
|
| [41] |
Han J, Kim YD, Woo KI, et al. Long-Term Outcomes of Eye-Sparing Surgery for Adenoid Cystic Carcinoma of Lacrimal Gland[J]. Ophthalmic Plast Reconstr Surg, 2018, 34(1): 74-78. doi: 10.1097/IOP.0000000000000877
|
| [42] |
柳睿, 张涵娟, 刘原照, 等. 眶颅沟通复发性泪腺腺样囊性癌的多学科病例讨论[J]. 眼科, 2021, 30(2): 161-165. https://www.cnki.com.cn/Article/CJFDTOTAL-YAKE202102028.htm
Liu R, Zhang HJ, Liu YZ, et al. Multidisciplinary case discussion of an orbitocranial communicating recurrent lacrimal gland adenoid cystic carcinoma[J]. Yan Ke, 2021, 30(2): 161-165. https://www.cnki.com.cn/Article/CJFDTOTAL-YAKE202102028.htm
|
| [43] |
Dewenter I, Otto S, Kakoschke TK, et al. Recent Advances, Systemic Therapy, and Molecular Targets in Adenoid Cystic Carcinoma of the Head and Neck[J]. J Clin Med, 2023, 12(4): 1463. doi: 10.3390/jcm12041463
|
| [44] |
Barcellini A, Fontana G, Filippini DM, et al. Exploring the role of neutrophil-to-lymphocyte ratio and blood chemistry in head and neck adenoid cystic carcinomas treated with carbon ion radiotherapy[J]. Radiother Oncol, 2022, 177: 143-151. doi: 10.1016/j.radonc.2022.10.027
|
| [45] |
Aljabab S, Lui A, Wong T, et al. A Combined Neutron and Proton Regimen for Advanced Salivary Tumors: Early Clinical Experience[J]. Cureus, 2021, 13(5): e14844.
|
| [46] |
Bertholet J, Mackeprang PH, Mueller S, et al. Organ-at-risk sparing with dynamic trajectory radiotherapy for head and neck cancer: comparison with volumetric arc therapy on a publicly available library of cases[J]. Radiat Oncol, 2022, 17(1): 122. doi: 10.1186/s13014-022-02092-5
|
| [47] |
Tan BF, Tan WCC, Wang FQ, et al. PSMA PET Imaging and Therapy in Adenoid Cystic Carcinoma and Other Salivary Gland Cancers: A Systematic Review[J]. Cancers (Basel), 2022, 14(15): 3585. doi: 10.3390/cancers14153585
|
| [48] |
Tse DT, Benedetto PW, Tse BC, et al. Neoadjuvant Intra-Arterial Cytoreductive Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma: A Long-Term Follow-up Study of a Trimodal Strategy[J]. Am J Ophthalmol, 2022, 240: 239-251. doi: 10.1016/j.ajo.2022.03.027
|
| [49] |
Savarese T, Abate A, Basnet RM, et al. Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study[J]. Sci Rep, 2022, 12(1): 9951. doi: 10.1038/s41598-022-14197-8
|
| [50] |
Ye L, Zhang L, Li R, et al. Combined all-trans retinoic acid with low-dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single-center, secondary analysis of a phaseⅡ study[J]. Cancer Med, 2023, 12(8): 9144-9155. doi: 10.1002/cam4.5653
|
| [51] |
Powell SK, Kulakova K, Kennedy S. A Review of the Molecular Landscape of Adenoid Cystic Carcinoma of the Lacrimal Gland[J]. Int J Mol Sci, 2023, 24(18): 13755. doi: 10.3390/ijms241813755
|
| [52] |
da Silva FJ, Carvalho de Azevedo J Jr, Ralph ACL, et al. Salivary glands adenoid cystic carcinoma: a molecular profile update and potential implications[J]. Front Oncol, 2023, 13: 1191218. doi: 10.3389/fonc.2023.1191218
|
| [53] |
Ferrarotto R, Sousa LG, Feng L, et al. PhaseⅡ Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma[J]. J Clin Oncol, 2023, 41(15): 2843-2851. doi: 10.1200/JCO.22.02221
|
| [54] |
Vieito M, Moreno V, Spreafico A, et al. Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors[J]. Clin Cancer Res, 2023, 29(18): 3592-3602. doi: 10.1158/1078-0432.CCR-23-0092
|
| [55] |
Viragova S, Aparicio L, Palmerini P, et al. Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma[J]. J Natl Cancer Inst, 2023, 115(7): 838-852. doi: 10.1093/jnci/djad062
|
| [56] |
Sousa LG, McGrail DJ, Lazar NF, et al. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors[J]. Clin Cancer Res, 2023, 29(16): 3162-3171. doi: 10.1158/1078-0432.CCR-23-0514
|
| [57] |
Zhang J, Yan X, Liu R, et al. Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland[J]. Cancer Manag Res, 2022, 14: 1023-1032. doi: 10.2147/CMAR.S352623
|
| 1. |
朱翩, 杨凡, 周浪. 多模态MRI在前列腺癌疗效评价中的应用. 中国CT和MRI杂志. 2025(07)
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: